OR WAIT 15 SECS
ADC Biotechnology will invest downstream formulation, fill/finish capabilities, and Lock-Release conjugation technology.
ADC Biotechnology (ADC Bio) announced on Nov. 14, 2018 that the company secured additional funding of £2.5 million from existing investors and company management to ensure the achievement of specific business goals within the company’s overarching corporate strategy.
“We are delighted to have obtained this additional injection of funds that will be used to support the company’s strategic aspirations, including conceptual design of a downstream formulation and filling operation to complement our existing bioconjugation operations at the Deeside facility. We are also looking to fully exploit our core Lock-Release technology to create a transformative manufacturing paradigm that will significantly streamline ADC manufacturing supply chains,” said Charlie Johnson, CEO of ADC Bio, in a company press statement.
The investment syndicate consists of Maven Capital Partners, Seneca Partners, the Development Bank of Wales, and Downing LLP. In April 2018, the company reported that it had secured funding from Downing LLP to bolster the company’s marketing and new business drive for quicker penetration into the US market.
“The investment has been secured in response to strong supportive trends from the ADC development sector and will be put to good use in our planned strategy to further differentiate our company’s unique technology and service offering,” said Johnson.
Source: ADC Biotechnology
Related Content:Outsourcing | Highly Potent Drugs | Contract Development Services | Development | Dosage Forms | Supplier News | API Synthesis and Manufacturing, Large Molecule | API Synthesis and Manufacturing, Small Molecule | Contract Manufacturing, Biopharmaceutical Production | Contract Manufacturing, Drug Substance, API